MarginsXMarginsX
Home › Markets › Health Care › BGMS

Bio Green Med Solution Inc. (BGMS)

BGMS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.6502
+1.55% on the day
Market cap
$4.3M
Nano cap
Revenue · 2025
$0
-100.0% on 2024
Net income · 2025
-$3.0M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1130166/000149315226013669/0001493152-26-013669-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerBGMS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001130166
SEC industry codeWholesale-Durable Goods, NEC
Incorporated inDE

Financials · 2025

LineValue
Revenue$0
Net income-$3.0M
Operating income-$8.4M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growth-100.0%
Cash$3.5M
Total assets$8.2M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
43.6 months
$3.5M cash at September 30, 2026
Share count, 1 year
+35.2%
2025-11-11 to 2026-11-11 · +188481.8% over 3 years
Going-concern doubt
Yes
10-Q filed November 12, 2026
Insider net buying, 12 months
-$4.7M
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"The Company's history of losses, negative cash flows from operations, liquidity resources currently on hand, and its dependence on the ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, have resulted in the assessment that there is substantial doubt about the Company's ability to continue as a going concern for a period of at"
10-Q 2026-11-12
Cash and burn$3.5M cash; operating cash flow -$238K a quarter.Report 2026-09-30
Shares outstanding6,622,794 (2026-11-11); 4,900,142 a year earlier; 12,642,822 three years earlier. 3y figure adjusted for splits (1-for-3600 overall).Cover page 2026-11-11
Reverse splits, 3 years3; latest 1-for-15 on 2025-07-07Source 2025-07-07
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-10-23
Exchange deficiency notices, 12 months2 (8-K item 3.01)8-K 2026-11-04
AuditorSFAI MALAYSIA PLT, Puchong, Malaysia; changed auditors 1 time in 24 months8-K 4.01 2025-08-28
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $4.7M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$454K-$449K-$287K$3.5MNo debt tags$2.2M10-Q 2026-11-12
Q2 2026
2026-06-30
$357K-$405K-$352K$3.8MNo debt tags$1.8M10-Q 2026-08-14
Q1 2026
2026-03-31
$743K-$197K-$278K$3.3MNo debt tagsNeeds four quarters10-Q 2026-05-15
Q4 2025
2025-12-31
$666K-$611K-$33K$3.5MNo debt tags$010-K 2026-03-30
Q3 2025
2025-09-30
$81K-$988K-$434K$3.8MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2025
2025-06-30
Not filed-$1.3M-$1.1M$4.3MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q1 2025
2025-03-31
Not filed-$81K-$3.2M$3.5MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q4 2024
2024-12-31
$0-$3.1M-$1.4M$3.1MNo debt tags$43K10-K 2026-03-30

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-11-12
Latest annual report10-K2026-03-30
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12
Latest proxyDEF 14A2026-04-27

Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-25.6%
1 month-30.4%
3 months-31.2%
Year to date-56.8%
1 year-52.2%
From 52-week high-64.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
KPRXKiora Pharmaceuticals Inc.$0.9820-20.16%$4.3M
NCNANuCana plc American Depositary Share$0.8631-7.46%$4.4M
TRAWTraws Pharma Inc.$0.2600+3.59%$4.0M
SKYESkye Bioscience Inc.$1.06-2.29%$4.7M
CANFCan-Fite Biopharma Ltd$1.56+9.86%$4.7M
IMNNImunon Inc.$0.5940-5.56%$3.9M
PCSAProcessa Pharmaceuticals Inc.$1.72-7.53%$4.8M
GELSGelteq Limited$0.3589-5.63%$3.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier